Working… Menu

At What Time Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01551836
Recruitment Status : Completed
First Posted : March 13, 2012
Last Update Posted : March 13, 2012
Information provided by (Responsible Party):

Brief Summary:
This will be a single centre, open label, randomised, two-way crossover study in healthy volunteers under semi-fed conditions. Two formulations of paracetamol, are being tested in this study to establish at what time point a therapeutic concentration of paracetamol in the blood is reached. Subjects will attend a screening visit to check if they are eligible for study participation then within 15 days they will check-in to the unit for a stay of approximately 48 hours (hrs). They will be given a single dose of one of the preparations on the first day and then the other preparation on the next day. Regular blood samples will be taken along with other assessments for safety.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: Paracetamol formulation 1 Drug: Paracetamol formulation 2 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Official Title: A Randomised, Two Way Crossover Study to Determine the Time at Which Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations
Study Start Date : June 2009
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009

Arm Intervention/treatment
Paracetamol formulation 1
Higher dose level of marketed paracetamol (compared to the other dosage arm)
Drug: Paracetamol formulation 1
formulation 1

Paracetamol formulation 2
Lower paracetamol concentrations
Drug: Paracetamol formulation 2
Formulation 2

Primary Outcome Measures :
  1. Mean time to therapeutic levels of plasma concentration [ Time Frame: within a single day ]

Secondary Outcome Measures :
  1. Mean plasma concentrations [ Time Frame: within a single day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males in good general heatlh and Body Mass Index between 19-28 kg/m2

Exclusion Criteria:

  • Disease

    1. Current liver impairment, renal impairment, history of or active gastrointestinal ulcers, uncontrolled hypertension, haemophilia or other bleeding disorders.
    2. Current or recurrent disease, within 12 months of the screening, that could affect the action, absorption or disposition of the study formulations or clinical or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure).
    3. Current or relevant previous history, within 12 months of the screening visit, of serious, severe or unstable physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study treatments or procedures.
  • Medications

    1. Current or regular use at screening of any prescription, herbal or Over the Counter (OTC) medication including paracetamol, aspirin, metaclopramide, domperidone, cholestyramine, angiotensin -converting enzyme (ACE) inhibitors, acetazolamide, anticonvulsants, diuretics, methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs) and oral hypoglycemics within the past 48 hrs and monoamine oxidase inhibitors, tricyclic antidepressants, beta blockers and anticoagulants such as warfarin and heparin within the past 2 weeks.
    2. Subjects who have taken any drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to the screening visit (some examples of inducers: barbiturates, theophylline; inhibitors: cimetidine, erythromycin).
    3. Subjects for whom the use of any of the study drugs is contraindicated.
  • Virology Screening Positive screening for serum Hepatitis B surface antigen, Hepatitis C antibodies or human immunodeficiency virus (HIV).
  • Drug Screen

    1. Positive urine screen for drugs of abuse at screening and/or Day-1.
    2. Positive alcohol breath test on Day-1.
  • Smoking

    1. Smoking more than five cigarettes a day.
    2. Prior (within 7 days of dosing on Day 1) or current use of any other nicotine containing products, other than cigarettes/pipes/cigars.
  • Blood donation Has donated blood or plasma or any other blood product within 3 months of the screening visit. Subjects for whom participation in this study would result in having donated more than 1500 ml of blood within the previous 12 months.
  • Nutrition

    1. Is a vegetarian or is under a sodium restricted diet.
    2. Has consumed poppy seed containing foods within 3 days prior to the screening visit and admission on Day -1.
    3. Has consumed food and beverages containing grapefruit, Seville oranges or marmalade within 24 hrs prior to admission on Day -1.
    4. Has consumed caffeine containing drinks or food (e.g. tea, coffee, chocolate and cola) 24 hrs prior to admission on Day -1.
    5. Has consumed alcohol 36 hrs prior to admission on Day -1.
  • Has undertaken any unusually strenuous physical activity 24 hrs prior to the screening visit or check-in on Day 1.
  • Weight Weight below 50 kg.
  • Haemoglobin Subjects with haemoglobin level below 12.0 gram /decilitre (dl).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01551836

Layout table for location information
United Kingdom
GSK Investigational Site
Belfast, N Ireland, United Kingdom, BT9 6AD
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT01551836     History of Changes
Other Study ID Numbers: E3870651
First Posted: March 13, 2012    Key Record Dates
Last Update Posted: March 13, 2012
Last Verified: March 2012
Keywords provided by GlaxoSmithKline:
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs